Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185562 | 0.81 | KCNA5 (0.49) | KCNA5SIGMAR1 | |
| SCHEMBL4194445 | 0.81 | KCNA5 (0.49) | KCNA5SIGMAR1 | |
| SCHEMBL4192201 | 0.77 | SIGMAR1 (0.49) | KCNA5SIGMAR1 | |
| SCHEMBL4186078 | 0.76 | SIGMAR1 (0.48) | KCNA5SIGMAR1MCHR1 | |
| SCHEMBL6500146 | 0.66 | CCR8 (0.78) | SIGMAR1CCR8DRD4DRD2MCHR1 | |
| SCHEMBL6507014 | 0.66 | CCR8 (0.78) | SIGMAR1CCR8DRD4DRD2MCHR1 | |
| SCHEMBL6503375 | 0.66 | CCR8 (0.78) | SIGMAR1CCR8DRD4DRD2MCHR1 | |
| SCHEMBL6498389 | 0.64 | CCR8 (0.89) | SIGMAR1CCR8DRD4DRD2MCHR1 | |
| SCHEMBL6498379 | 0.64 | CCR8 (0.89) | SIGMAR1CCR8DRD4DRD2MCHR1 | |
| SCHEMBL4180562 | 0.64 | ABCB1 (0.42) | KCNA5SIGMAR1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | KCNA5 929/4885SIGMAR1 133/4885CCR8 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.